The DOI matches its Crossref record; 52 of the 52 references it cites were found in a registry or an index.
Affibody molecules: Engineered proteins for therapeutic, diagnostic and biotechnological applications
Open accessAbstract
Affibody molecules are a class of engineered affinity proteins with proven potential for therapeutic, diagnostic and biotechnological applications. Affibody molecules are small (6.5 kDa) single domain proteins that can be isolated for high affinity and specificity to any given protein target. Fifteen years after its discovery, the Affibody technology is gaining use in many groups as a tool for creating molecular specificity wherever a small, engineering compatible tool is warranted. Here we summarize recent results using this technology, propose an Affibody nomenclature and give an overview of different HER2‐specific Affibody molecules. Cumulative evidence suggests that the three helical scaffold domain used as basis for these molecules is highly suited to create a molecular affinity handle for vastly different applications.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A synthetic IgG-binding domain based on staphylococcal protein A
Nilsson, B., Moks, T., Jansson, B., Abrahmsén, L., Elmblad, A., Holmgren, E., Henrichson, C., Jones, T. A., & Uhlén, M. (1987) · "Protein Engineering, Design and Selection" · doi:10.1093/protein/1.2.107 · Cited by 759
Engineering novel binding proteins from nonimmunoglobulin domains
Binz, H. K., Amstutz, P., & Plückthun, A. (2005) · Nature Biotechnology · doi:10.1038/nbt1127 · Cited by 676
Binding proteins selected from combinatorial libraries of an α-helical bacterial receptor domain
Nord, K., Gunneriusson, E., Ringdahl, J., Ståhl, S., Uhlén, M., & Nygren, P.-Å. (1997) · Nature Biotechnology · doi:10.1038/nbt0897-772 · Cited by 662
Self-citationTumor Imaging Using a Picomolar Affinity HER2 Binding Affibody Molecule
Orlova, A., Magnusson, M., Eriksson, T. L. J., Nilsson, M., Larsson, B., Höidén-Guthenberg, I., Widström, C., Carlsson, J., Tolmachev, V., Ståhl, S., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-3521 · Cited by 568
Self-citationUhlén, M., Guss, B., Nilsson, B., Gatenbeck, S., Philipson, L., & Lindberg, M. (1984) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)43463-6 · Cited by 566
Pastan, I., Hassan, R., FitzGerald, D. J., & Kreitman, R. J. (2006) · Nature Reviews Cancer · doi:10.1038/nrc1891 · Cited by 528
New approaches for imaging tumour responses to treatment
Brindle, K. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2289 · Cited by 460
Stabilization of a β-hairpin in monomeric Alzheimer's amyloid-β peptide inhibits amyloid formation
Hoyer, W., Grönwall, C., Jonsson, A., Ståhl, S., & Härd, T. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0711731105 · Cited by 410
Self-citationTargeted therapy of cancer with radiolabeled antibodies.
Goldenberg, D. M. (2002) · PubMed · Cited by 318
Baum, R. P., Prasad, V., Müller, D., Schuchardt, C., Orlova, A., Wennborg, A., Tolmachev, V., & Feldwisch, J. (2010) · Journal of Nuclear Medicine · doi:10.2967/jnumed.109.073239 · Cited by 308
Self-citation
Cited by
Liposomes as nanomedical devices
Bozzuto, G., & Molinari, A. (2015) · International Journal of Nanomedicine · doi:10.2147/ijn.s68861 · Cited by 2,261
Contrast agents for molecular photoacoustic imaging
Weber, J., Beard, P. C., & Bohndiek, S. E. (2016) · Nature Methods · doi:10.1038/nmeth.3929 · Cited by 1,270
Harnessing albumin as a carrier for cancer therapies
Hoogenboezem, E. N., & Duvall, C. L. (2018) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2018.07.011 · Cited by 610
Srinivasarao, M., & Low, P. S. (2017) · Chemical Reviews · doi:10.1021/acs.chemrev.7b00013 · Cited by 605
Nanobodies as therapeutics: big opportunities for small antibodies
Steeland, S., Vandenbroucke, R. E., & Libert, C. (2016) · Drug Discovery Today · doi:10.1016/j.drudis.2016.04.003 · Cited by 468
A Global Review on Short Peptides: Frontiers and Perspectives
Apostolopoulos, V., Bojarska, J., Chai, T.-T., Elnagdy, S., Kaczmarek, K., Matsoukas, J., New, R., Parang, K., Lopez, O. P., Parhiz, H., et al. (2021) · Molecules · doi:10.3390/molecules26020430 · Cited by 421
Chemical Protein Modification through Cysteine
Gunnoo, S. B., & Madder, A. (2016) · ChemBioChem · doi:10.1002/cbic.201500667 · Cited by 407
Currin, A., Swainston, N., Day, P. J., & Kell, D. B. (2015) · Chemical Society Reviews · doi:10.1039/c4cs00351a · Cited by 388
Affibody Molecules in Biotechnological and Medical Applications
Ståhl, S., Gräslund, T., Eriksson Karlström, A., Frejd, F. Y., Nygren, P.-Å., & Löfblom, J. (2017) · Trends in Biotechnology · doi:10.1016/j.tibtech.2017.04.007 · Cited by 382
Self-citationNucleic Acid and Peptide Aptamers: Fundamentals and Bioanalytical Aspects
Mascini, M., Palchetti, I., & Tombelli, S. (2012) · Angewandte Chemie International Edition · doi:10.1002/anie.201006630 · Cited by 374
Recent trends in protein and peptide-based biomaterials for advanced drug delivery
Varanko, A., Saha, S., & Chilkoti, A. (2020) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2020.08.008 · Cited by 369
Emerging advances in nanomedicine with engineered gold nanostructures
Webb, J. A., & Bardhan, R. (2014) · Nanoscale · doi:10.1039/c3nr05112a · Cited by 324
Progress in bacterial cellulose matrices for biotechnological applications
Cacicedo, M. L., Castro, M. C., Servetas, I., Bosnea, L., Boura, K., Tsafrakidou, P., Dima, A., Terpou, A., Koutinas, A., & Castro, G. R. (2016) · Bioresource Technology · doi:10.1016/j.biortech.2016.02.071 · Cited by 306
Nonspecific Binding—Fundamental Concepts and Consequences for Biosensing Applications
Frutiger, A., Tanno, A., Hwu, S., Tiefenauer, R. F., Vörös, J., & Nakatsuka, N. (2021) · Chemical Reviews · doi:10.1021/acs.chemrev.1c00044 · Cited by 278
Nanobodies: Chemical Functionalization Strategies and Intracellular Applications
Schumacher, D., Helma, J., Schneider, A. F. L., Leonhardt, H., & Hackenberger, C. P. R. (2018) · Angewandte Chemie International Edition · doi:10.1002/anie.201708459 · Cited by 260
Sörensen, J., Sandberg, D., Sandström, M., Wennborg, A., Feldwisch, J., Tolmachev, V., Åström, G., Lubberink, M., Garske-Román, U., Carlsson, J., et al. (2014) · Journal of Nuclear Medicine · doi:10.2967/jnumed.113.131243 · Cited by 258
Self-citationAffibody molecules as engineered protein drugs
Frejd, F. Y., & Kim, K.-T. (2017) · Experimental & Molecular Medicine · doi:10.1038/emm.2017.35 · Cited by 225
Self-citationBiomolecular sensors for advanced physiological monitoring
Flynn, C. D., Chang, D., Mahmud, A., Yousefi, H., Das, J., Riordan, K. T., Sargent, E. H., & Kelley, S. O. (2023) · Nature Reviews Bioengineering · doi:10.1038/s44222-023-00067-z · Cited by 226
The Dawn of a New Era: Targeting the “Undruggables” with Antibody-Based Therapeutics
Qian, L., Lin, X., Gao, X., Khan, R. U., Liao, J.-Y., Du, S., Ge, J., Zeng, S., & Yao, S. Q. (2023) · Chemical Reviews · doi:10.1021/acs.chemrev.2c00915 · Cited by 155
Advances in targeted degradation of endogenous proteins
Röth, S., Fulcher, L. J., & Sapkota, G. P. (2019) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-019-03112-6 · Cited by 92
(2025) · doi:10.1021/acs.biomac.5c00097 · Cited by 5
Katzschmann, A., Haupts, U., Reimann, A., Settele, F., Gloser-Bräunig, M., Fiedler, E., & Parthier, C. (2024) · Communications Biology · doi:10.1038/s42003-024-06569-9 · Cited by 2
Metadata
- Authors
- Löfblom, J., Feldwisch, J., Tolmachev, V., Carlsson, J., Ståhl, S., & Frejd, F. Y.
- Venue
- FEBS Letters
- Publisher
- Wiley
- Published
- 2010-04-11
- Volume
- 584
- Issue
- 12
- Pages
- 2670-2680
- ISSN
- 0014-5793 (ISSN-L)
- 1873-3468
- OpenAlex
- W2077787026
- Cited by
- 651
- References
- 52
- FWCI
- 28.93
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.